Chantal Quinten of the European Organization for
Research and Treatment of Cancer (EORTC) presented a meta-analysis of 30 EORTC trials involving 10 000 patients. 4 The trials included baseline QOL measurements using the EORTC QLQ-C30 survey form. This form assesses QOL using 15 standard scales. A Cox proportional hazards analysis was used to determine the relationship of the separate QOL scales to survival. Age, sex, presence of distant metastases, performance status, and disease site were controlled for in the statistical analysis. Even after controlling for all these variables, Quinten and colleagues found that physical functioning, cognitive functioning, global health status, fatigue, nausea and vomiting, dyspnea, and appetite loss all predicted survival at highly significant levels (P < .016-.0001).
Perhaps appropriately, both investigators offered conservative interpretations of their data-that QOL could be used to help predict survival and that it should be used to stratify patients for further clinical trials. And it is clear that QOL variables are, to a certain extent, simply manifestations of biological processes in advancing cancer, particularly variables like appetite loss, pain, and dyspnea. But the investigators also mentioned to Medscape reporters 2 that if doctors can identify patients with impaired quality of life and then intervene to improve their well-being, they may be able to lengthen life span.
I strongly concur with this conclusion, based on years of clinical work aimed at improving patients' physical functioning, fatigue levels, side effects, and overall health-and seeing results in both overall QOL and survival. These findings should give renewed impetus to the study and use of integrative and complementary therapies. Even the therapies that are, rather oddly, perceived as "soft," like yoga, massage, or psychoeducational work (in contrast to "hard" therapies like nutrition and supplements) can have significant roles in helping patients get better-above and beyond simply feeling better.
The research challenge before us now is to determine whether by improving already impaired QOL, we can affect the survival of cancer patients. I predict that studies that focus on single interventions-a series of yoga classes, a series of massages-will be hard-pressed to demonstrate more than minimal statistical impacts on I have mentioned before in these editorials an experience at a national conference in which a speaker distinguished 3 dimensions of cancer treatment as feeling better, living better, and getting better. 1 A very clear line was drawn between the feeling-better-and-living-better aspects of care-dimensions for which integrative medicine or CAM has what was described as a reasonable roleand modalities for getting better, deemed the exclusive province of conventional oncology. I believe that this was an inappropriate and troubling distinction and that systematic integrative medicine incorporating CAM can mean excellent, comprehensive medicine and thus can be instrumental to getting better. Integrative by definition means not separating the dimensions in a false dichotomy. At this year's American Society of Clinical Oncology (ASCO) meeting in early June, 2 studies were presented that gave additional validation to this point. 2 These 2 studies were both meta-analyses of clinical oncology trials in which patients completed baseline quality of life (QOL) questionnaires. Dr Angelina Tan of the Mayo Clinic presented an analysis of 24 North Central Cancer Treatment Group and Mayo Clinic trials involving more than 3700 patients. 3 The survey instrument used in these trials uses a 0-to 100-point scale. A Cox proportional hazards model was used to analyze QOL and survival data, adjusted for performance status, race, site, age, and sex. Baseline QOL strongly and independently predicted survival. The authors presented their data in a compelling way that pulls our attention to the survival differences. The patients were first divided into 2 groups according to whether their QOL scores were above or below the median QOL score (83 points). Those below the median survived an average of 12.3 months whereas those above the median survived 18.4 months-a highly significant difference. The investigators also split the patient population into those who had clinically deficient QOL (0-50 points) and those who were not clinically deficient (50-100 points). Those with clinically deficient QOL lived an average of 9.3 months whereas those who were not clinically deficient lived for 16.8 months, again highly significant. These startling differences were consistent across gastrointestinal, genitourinary, lung, breast, and brain cancers.
survival. We are only likely to be able to show significant effects by affecting multiple QOL targets to bring about large and clinically significant QOL changes. The ASCO findings present a challenge to funding agencies to develop a financial basis for studying integrated QOL interventions that include both hard and soft modalities. Initially, projects should attempt to demonstrate clinically significant influences on multiple-dimension QOL scales, such as the EORTC or FACT instruments. Only when such improvement has been shown should projects move to a randomized setting. If the preliminary step is omitted, we run the risk of declaring that a particular program has no effect on survival when, in fact, it did not even show a clear benefit to quality of life.
One of our articles in this issue concerns an alternative cancer therapy that has long been associated with some of the softer aspects of CAM, anthroposophic therapy-our first article on this system, which was originated by the founder of Waldorf Education, Rudolf Steiner. Anthroposophic oncology has, in addition to modalities such as art therapy and eurhythmic massage, a variety of medicines based on mistletoe extracts and homeopathic formulations. It is widely used in Europe. Walter Legnani, an Italian oncologist, reviews the background and bases of this therapy and then presents several cases as examples of how it can be integrated into oncology practice. This article is a useful educational review on the integrative use of this therapy.
Two other articles hail from Europe in this very international issue of ICT. Georgios Koukourakis and colleagues present an educational review of granulosa tumors of the ovary, consistent with our aim to provide high-level conventionally based educational materials. Granulosa tumors are a rare form of ovarian cancer, and the authors have developed an exhaustive review of treatment options for this subject. Gabor Somlyai and colleagues present a case series of patients using deuteriumdepleted water, an alternative cancer therapy that has been developed in Hungary. The patients in this series all had brain metastases from lung cancer and had exhausted their mainstream treatment options, so the outcomes described in this article are quite interesting.
Another international contribution to the issue is the article by Hwa Seung Yoo and colleagues on a best case series project submitted to the Office of Cancer Complementary and Alternative Medicine (OCCAM) at the U.S. National Cancer Institute. We have published previous results of best case series investigations, although this is the first to be submitted solely by the originators of the cases. Of special interest for centers contemplating submission of a best case series, Yoo and colleagues discuss the difficulties involved in assembling such cases that may be useful to other investigators. They also reflect on the policy of OCCAM to accept only evidence of tumor regression and not of disease stabilization/tumor dormancy in assessing best cases.
Yet another international submission in this issue is the review of melatonin in cancer submitted by Daniel Cardinali and colleagues. This lengthy review of melatonin is a thorough assessment of the multiple facets of melatonin in cancer treatment and is essential reading for anyone working with this fascinating compound.
Gordon Saxe and colleagues present a follow-up to a study previously published in this journal concerning a trial of a diet and stress reduction intervention in prostate cancer. 5, 6 This report examines biological mediators of the changes observed in the trial, including measurements such as waist-hip ratio, weight, prostate-specific antigen, testosterone, estradiol, sex hormone binding globulin, interleukin-6, and tumor necrosis factor-α. This study offers important insights into the ability of diet and stress reduction to change the internal hormonal milieu in cancer patients. This is certainly one of the most crucial steps needed to validate the clinical effects of integrative cancer interventions.
We are very pleased to be able to present one of the reports resulting from the WHEL study in this issue. Gordon Saxe, John Pierce, and other WHEL study members used a questionnaire administered as part of the WHEL study to examine patterns of disclosure of CAM use among the breast cancer patients participating in the study. This article is particularly interesting in its examination of the use of CAM interventions that are delivered by practitioners who can be viewed as alternative primary care practitioners-homeopaths, naturopaths, acupuncturists, and chiropractors. An interesting difference emerges in the rates at which breast cancer patients report visits to practitioners of chiropractic versus the other 3 therapies, chiropractic being the most frequently used therapy after completion of breast cancer treatment.
We also feature another article on patterns of CAM use among cancer patients. An-Fu Hsiao and colleagues present results of a survey on how religion and spirituality are reflected in the patterns of CAM use by cancer survivors in California. Although many reviews of factors associated with CAM use have been published, the spiritual dimension has not been reflected in many of them. Hsiao and coauthors demonstrate that the spiritual dimension has distinct effects on CAM use. They explore this in light of the widespread and interesting phenomenon of persons who feel they are "spiritual but not religious."
Also in this issue, Uma Gupta and colleagues explore the radioprotective effects of the Ayurvedic herb Alstonia scholaris in the hematological system of mice. This herb, interestingly, has already been shown to have a radiosensitizing effect, increasing the life spans of mice with implanted tumors that were irradiated in comparison with control tumor-bearing mice that were irradiated without herbal treatment. 7 Thus, this herb may have potential as a normal tissue protectant that simultaneously increases the effects of radiation. The article by Gupta et al aids in our understanding of the mechanisms of this normal tissue protection. Protection of the hematological system during radiation is certainly a clinically relevant observation. This finding is of major interest and should be explored further.
Karen Wonders and colleagues present an animal study on the potential efficacy of using aerobic exercise to protect against cardiotoxicity attributable to doxorubicin. Doxorubicin toxicity is a serious problem, especially because it limits the dosing of this important chemotherapy drug. Wonders' study demonstrates that even a single bout of acute exercise can ameliorate cardiotoxic effects, suggesting that the presence of exercise equipment in chemotherapy units should be widespread if not universal. My experience in housing a physical therapy center in my community-based chemotherapy clinic is that exercise affects many aspects of cancer. It is also one of the key features needed to improve quality of life for cancer patients and thus, potentially, affect their survival as well.
Keith I. Block, MD

Editor-in-Chief Integrative Cancer Therapies Block Center for Integrative Cancer Treatment Evanston, Illinois University of Illinois at Chicago College of Medicine and College of Pharmacy
Chicago, Illinois
